Ulcerative colitis (uc) Trials in Berlin, Germany
Conditions / Ulcerative colitis (uc) / Berlin, Germany
Clinical trials for Ulcerative colitis (uc) investigate a range of treatment strategies and patient populations.
12 total trials for this combination
Showing top 10 of 12 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02065622 | Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis | COMPLETED | PHASE3 |
| NCT03920254 | TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study | TERMINATED | PHASE2/PHASE3 |
| NCT03695185 | A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy | COMPLETED | PHASE2 |
| NCT01848561 | A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) | ACTIVE_NOT_RECRUITING | — |
| NCT03758443 | Efficacy & Safety of TD-1473 in Ulcerative Colitis | TERMINATED | PHASE2/PHASE3 |
| NCT02819635 | A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) | COMPLETED | PHASE2/PHASE3 |
| NCT03006068 | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03653026 | A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis | COMPLETED | PHASE3 |
| NCT03398135 | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03398148 | A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis | COMPLETED | PHASE2/PHASE3 |